Market Place
Sourcing Support
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu News
09 Nov 2024 //
PHARMAPHORUM
Alteogen`s Tergase Shows Excellent Immunogenicity Profile
05 Sep 2023 //
PR NEWSWIRE
Altos Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea
22 Feb 2023 //
PR NEWSWIRE
Sandoz, Alteogen sign license agreement for biosimilar products
03 Jan 2023 //
BUSINESSWIRE
Alteogen Announces Completion of Ph1 Clinical Trial of Aflibercept Biosimilar
08 Mar 2021 //
BUSINESSWIRE
Alteogen Announces Completion of Ph1 Clinical Trial of Aflibercept Biosimilar
08 Mar 2021 //
BUSINESSWIRE
Alteogen Enters Into an Exclusive License Agreement With Intas
07 Jan 2021 //
BUSINESSWIRE
Alteogen Enters into a Global License Agreement with Top Ten Pharma Hybrozyme™
24 Jun 2020 //
BUSINESSWIRE
Alteogen Enters into a Global License Agreement with a Top Ten Pharma
24 Jun 2020 //
BUSINESSWIRE
Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting (ADC)
29 May 2020 //
BUSINESSWIRE
Alteogen Enters into a Non-exclusive License Agreement a Global Pharma Company
02 Dec 2019 //
BUSINESS WIRE
Alteogen wins FDA orphan drug status for gastric cancer therapy
02 Aug 2019 //
THEINVESTOR
Alteogen to supply Herceptin biosimilar for LinXis’ ADC therapy
28 Mar 2018 //
THEINVESTOR
3SBio, Alteogen to develop antibody for metastatic cancer
13 Oct 2015 //
BIOSPECTRUM ASIA
HK-listed 3SBio inks oncology antibody drug deal with South Korea`s Alteogen
12 Oct 2015 //
FIERCE PHARMA ASIA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.